Growth Outcomes After 48 Weeks of Dolutegravir in Children and Adolescents With HIV-1 in IMPAACT P1093 and IMPAACT 2019
Open Access
- 12 September 2026
- journal article
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 15 (10)
Abstract
Background: We evaluated growth outcomes in children and adolescents with HIV-1 initiating or switching to dolutegravir-based antiretroviral therapy (ART) in the single-arm International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network studies P1093 and IMPAACT 2019. Methods: We performed descriptive post hoc analyses of body mass index–for-age (BAZ), weight-for-age (WAZ), and length/height-for-age z scores (L/HAZ) for each trial through Week 48. Changes in BAZ were assessed using a mixed model for repeated measures. Results: We included data from 181 and 57 participants from P1093 and IMPAACT 2019, respectively (10% [23/238] were adolescents). Baseline mean BAZ was −0.1 in P1093 and −0.7 in IMPAACT 2019. At Week 48, adjusted mean BAZ increased significantly in P1093 (0.3; 95% CI, 0.03, 0.49; P < .05) and non-significantly in IMPAACT 2019 (0.3; 95% CI, −0.03, 0.58; P = .074). Mean BAZ was in the normal range at Week 48 in both trials. Marked increases in BAZ were observed among subgroups with baseline BAZ <−2. By Week 48, 65% (117/181) of participants in P1093 and 74% (42/57) in IMPAACT 2019 remained in the same BAZ category. Improvements from severe or moderate malnutrition/thinness to normal weight occurred in 6% (10/181) and 7% (4/57) of participants in P1093 and IMPAACT 2019, respectively, while increases to overweight or obesity were observed in 9% (16/181) and 5% (3/57). Small changes were observed in overall mean WAZ and L/HAZ through Week 48 in both trials. Conclusion: Small overall increases in BAZ were observed over 1 year among pediatric participants on dolutegravir-based ART, with most participants remaining in their baseline BAZ category. Clinical trial information: ClinicalTrials.gov, NCT01302847 and NCT03760458.Keywords
Funding Information
- ViiV Healthcare
- International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network
- National Institute of Allergy and Infectious Diseases
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Institute of Mental Health
- National Institutes of Health (UM1AI068632)
- National Institutes of Health (UM1AI068616)
- National Institutes of Health (UM1AI106716)
- National Institute of Child Health and Human Development (HHSN275201800001I)
This publication has 19 references indexed in Scilit:
- Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trialThe Lancet Child & Adolescent Health, 2026
- Cardiometabolic health in people with HIV: expert consensus reviewJournal of Antimicrobial Chemotherapy, 2024
- Antiretrovirals and Weight Change: Weighing the EvidenceClinical Infectious Diseases, 2024
- Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1–2 dose-confirmation studyThe Lancet HIV, 2023
- Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trialThe Lancet HIV, 2022
- Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trialThe Lancet HIV, 2022
- Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in ChildrenNew England Journal of Medicine, 2021
- Genetics of Obesity: What We Have Learned Over Decades of ResearchObesity, 2021
- Transition to Dolutegravir Is Associated With an Increase in the Rate of Body Mass Index Change in a Cohort of Virally Suppressed AdolescentsClinical Infectious Diseases, 2020
- The epidemiology of obesityMetabolism, 2019